GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alkem Laboratories Ltd

Alkem Labs Q1 FY27 Consolidated Revenue from Operations at ₹37,401.5 Million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 14 Aug 2026, 01:53 PM IST  ·  BSE ID: 20e45b3e-1bfa-43f9-b4c2-8668b09535e7
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories has released its financial results for the first three months of the fiscal year 2027.
🤖 AI Summary
  • Alkem Laboratories' Board approved Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
  • Revenue from Operations reached ₹37,401.5 Million for the quarter, up from ₹33,711.4 Million YoY.
  • Profit before tax for Q1 FY27 was ₹7,719.9 Million, compared to ₹7,710.1 Million in Q1 FY26.
  • Total Tax Expense for the quarter ended June 30, 2026, stood at ₹2,505.0 Million.
  • Consolidated Profit after tax was ₹5,209.8 Million for the quarter.
  • The Board meeting commenced at 11:00 a.m. and concluded at 01:40 p.m. on August 14, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from Operations
37,401.5 Million
10.95%
Consolidated Profit before tax
7,719.9 Million
0.13%
Consolidated Profit after tax
5,209.8 Million
4.99%
Total Tax Expense
2,505.0 Million
144.91%
🏢 How This Affects the Company
📈
Business Impact
The company reported a 10.95% increase in Consolidated Revenue from Operations, reaching ₹37,401.5 Million for the quarter ended June 30, 2026, indicating continued business activity.
💰
Financial Impact
Consolidated Profit after tax for the quarter was ₹5,209.8 Million, reflecting the company's profitability in the initial quarter of FY27.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All existing shareholders are affected by these financial results, which confirm the company's performance for the quarter ended June 30, 2026.
🔍
Management Signal
The approval and disclosure of unaudited financial results signal management's adherence to regulatory compliance and transparent reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 financial results — check for sustained revenue growth and cost management.
Any further exceptional items disclosures — monitor their impact on profitability.
Review of subsidiary performance, especially those not audited by primary auditors.
MEDIUM RISK Increased finance costs and other expenses, alongside a significant jump in tax expense, merit closer monitoring.
💡 Investor Takeaway
Alkem Laboratories reported consolidated Revenue from Operations of ₹37,401.5 Million for Q1 FY27, a 10.95% increase from ₹33,711.4 Million in Q1 FY26. Consolidated Profit after tax stood at ₹5,209.8 Million, up from ₹4,961.8 Million YoY.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from Operations increased by 10.95% to ₹37,401.5 Million for Q1 FY27 from ₹33,711.4 Million in Q1 FY26.
  • Profit before tax for Q1 FY27 was ₹7,719.9 Million, marginally higher than ₹7,710.1 Million in Q1 FY26.

⚠️ Concerns

  • Other expenses increased by 25.57% to ₹9,639.3 Million in Q1 FY27 from ₹7,676.8 Million in Q1 FY26.
  • Finance costs increased by 56.55% to ₹466.2 Million in Q1 FY27 from ₹297.8 Million in Q1 FY26.
📅 Company Track Record
Alkem Laboratories reported record FY26 EBITDA of ₹30,052 million and 14.6% Q4 FY26 revenue growth in a filing on May 28, 2026. The company also approved FY26 results and recommended a ₹10 final dividend at that time.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Alkem Laboratories' consolidated revenue from operations for Q1 FY27?
Alkem Laboratories reported a consolidated Revenue from Operations of ₹37,401.5 Million for the quarter ended June 30, 2026, an increase from ₹33,711.4 Million in the prior year.
What was Alkem Laboratories' consolidated profit after tax for the quarter ended June 30, 2026?
The consolidated Profit after tax for Alkem Laboratories was ₹5,209.8 Million for the quarter ended June 30, 2026.
How did Alkem Laboratories' total tax expense change in Q1 FY27?
Alkem Laboratories' Total Tax Expense increased to ₹2,505.0 Million for Q1 FY27, up from ₹1,026.9 Million in the corresponding quarter of the previous year.
What was the profit before tax for Alkem Laboratories in Q1 FY27?
Alkem Laboratories' consolidated Profit before tax was ₹7,719.9 Million for the quarter ended June 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.